GHTF (Global Harmonization Task Force) lists SG1 members:
This article was originally published in Clinica
The Global Harmonization Task Force has posted an updated directory of members of study group 1, regulatory requirements and premarket review, on its website. The chair of this group is senior medical device consultant Maurice Freeman, and the secretary, former chief executive of the UK's Medical Devices Agency, Alan Kent.
You may also be interested in...
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.
FDA has little in the way of good information it can list on its CBD policy agenda so far, says Principal Deputy Commissioner Amy Abernethy. At recent regulatory conference, she said, "Like it or not, there is a massive human experiment going on right now. There’s CBD in most different product categories and people of many different backgrounds with potential vulnerabilities taking CBD."
FDA is worried about drug names that could appear to overstate efficacy and impact consumer and healthcare provider perceptions of the product.